drugset / Trial / NCT06706427
Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects
NaSequentialOpen-labelTreatment
Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of subretinal injection of NGGT001 in patients with Bietti Crystalline Corneoretinal Dystrophy (BCD) and to recommend the optimal dosage for future clinical administration.
Timeline
- Start
- 2024-03-21
- Primary completion
- 2025-11-30
- Completion
- 2029-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NGGT001 | Gene therapy (AAV / viral vector) | — | Other |